USA: The RECOVER Initiative - Long Covid research
- Thread starter rvallee
- Start date
Maybe i should reply on bluesky but LDN and Baricitinib are already being thoroughly trialed (although I guess LDN is being trialed in ME). GLP1 is an interesting idea I suppose, not sure what the rationale is. As for SGB, I am really skeptical, but I suppose it's better to have a trial than not so we have a clear result.
Deeply disappointing lineup imo.
Deeply disappointing lineup imo.
Yann04
Senior Member (Voting Rights)
Agreed. And in anycase I’d rather have it go towards solid biomed research than another treatment trial with long covid (which is such a vague clinical construct very unlikely a treatment works for most cases). If they’re insisting on treatment trial much rather they’d do a well defined subset.
Pinging @Dakota15 given they were interested in knowing people’s opinions.
Dakota15
Senior Member (Voting Rights)
From Ezra Spier (LC Patient Advocate was at Keystone Symposium) on Bluesky:
'A couple important Long COVID clinical trial announcements from Keystone that I want to share!"
"1. BioVie has announced that they changed their protocol and are now allowing people who have had LC for more than 2 years to participate. Here’s the press release: investors.bioviepharma.com/news/news-de...More study sites have been added and more are still to come. More at addresslongcovid.com"
"2. Wes Ely announced that his National Institute of Aging-funded REVERSE-LC trial of baricitinib will now be cosponsored by NIAID as part of RECOVER-TLC and will expand from 4 to 15 sites. The sites are currently being selected, but more info on the trial is here: www.reversinglongcovid.org"
3. "Finally, just a comment from me: the researchers at the conference were incredibly enthusiastic and committed to the field. Funding, logistical, and scientific challenges remain, but the enthusiasm and creativity on display was so energizing (and I've got LC so that really means something)."
'A couple important Long COVID clinical trial announcements from Keystone that I want to share!"
"1. BioVie has announced that they changed their protocol and are now allowing people who have had LC for more than 2 years to participate. Here’s the press release: investors.bioviepharma.com/news/news-de...More study sites have been added and more are still to come. More at addresslongcovid.com"
"2. Wes Ely announced that his National Institute of Aging-funded REVERSE-LC trial of baricitinib will now be cosponsored by NIAID as part of RECOVER-TLC and will expand from 4 to 15 sites. The sites are currently being selected, but more info on the trial is here: www.reversinglongcovid.org"
3. "Finally, just a comment from me: the researchers at the conference were incredibly enthusiastic and committed to the field. Funding, logistical, and scientific challenges remain, but the enthusiasm and creativity on display was so energizing (and I've got LC so that really means something)."
This trial has been enrolling people for a while right? Does this imply they are seeing positive responses? Ofc they wouldn't know if it was drug or placebo at this point, but thats a big expansion and a big investment for RECOVER. Not that they have used their previous funding wisely...
Last edited:
Dakota15
Senior Member (Voting Rights)
From Bluesky:
'NIH researchers are collecting tissue from people with and without long COVID to see if viral remnants of SARS-CoV-2 persist in the body and whether they differ in type or amount between the two groups.'
8/3/25, NINDS: 'Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection'
Study Contacts: Avindra Nath, M.D. & Angelique A Gavin
'NIH researchers are collecting tissue from people with and without long COVID to see if viral remnants of SARS-CoV-2 persist in the body and whether they differ in type or amount between the two groups.'
8/3/25, NINDS: 'Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection'
Study Contacts: Avindra Nath, M.D. & Angelique A Gavin
Dakota15
Senior Member (Voting Rights)
Some updated names I quickly see listed on the updated agenda for he upcoming RECOVER-TLC workshop on Sept. 9–10:
- Dr. Peter Rowe, Johns Hopkins
- Dr. David Kaufman, Center for Complex Diseases
- Jessica Martinez, Gates Foundation
- Dr. Amy Proal, PolyBio
- Dr. Peter Rowe, Johns Hopkins
- Dr. David Kaufman, Center for Complex Diseases
- Jessica Martinez, Gates Foundation
- Dr. Amy Proal, PolyBio
Dakota15
Senior Member (Voting Rights)
Text:
'Former NIH Director Dr. Monica Bertagnolli opening remarks on 10/22/25, 12th Annual FNIH Awards Ceremony
MB: “We look forward to continuing to work with the Foundation for the NIH on new priority NIH programs such as RECOVER-TLC, which will evaluate treatments for Long COVID”
'Former NIH Director Dr. Monica Bertagnolli opening remarks on 10/22/25, 12th Annual FNIH Awards Ceremony
MB: “We look forward to continuing to work with the Foundation for the NIH on new priority NIH programs such as RECOVER-TLC, which will evaluate treatments for Long COVID”